Novo Nordisk has introduced Wegovy, a once-weekly semaglutide injection, in India. The medication is the first GLP-1 receptor agonist in the country to receive approval for both long-term weight management and the reduction of major cardiovascular events. This marks a significant development in treatment options for individuals dealing with obesity and related health risks..

诺和诺德已在印度推出了一款每周一次的司美格鲁肽注射剂Wegovy。该药物是印度首个获批用于长期体重管理和降低主要心血管事件的GLP-1受体激动剂。这标志着针对肥胖及相关健康风险人群的治疗选择取得了重要进展。

Wegovy’s approval allows it to address two critical health concerns: chronic weight management and cardiovascular risk reduction. The drug functions as a glucagon-like peptide-1 (GLP-1) receptor agonist, which is designed to regulate appetite and improve metabolic health. Its once-weekly administration offers a convenient option for patients requiring sustained intervention.

Wegovy的批准使其能够解决两个关键的健康问题：慢性体重管理和心血管风险降低。该药物作为一种胰高血糖素样肽-1（GLP-1）受体激动剂，旨在调节食欲并改善代谢健康。每周一次的给药方式为需要持续干预的患者提供了便利的选择。

Novo Nordisk’s launch of this product aligns with growing global efforts to combat obesity and its associated complications, including heart disease..

诺和诺德推出该产品，与全球日益增长的抗击肥胖及其相关并发症（包括心脏病）的努力相契合。